Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies.

Havrdova, E

Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies. [electronic resource] - European journal of neurology May 2017 - 726-733 p. digital

Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial

1468-1331

10.1111/ene.13272 doi


Adult
Delayed-Action Preparations
Dimethyl Fumarate--administration & dosage
Disease Progression
Female
Glatiramer Acetate--administration & dosage
Humans
Immunosuppressive Agents--administration & dosage
Magnetic Resonance Imaging--methods
Male
Middle Aged
Multiple Sclerosis, Relapsing-Remitting--diagnostic imaging
Recurrence
Treatment Outcome